Deeply undervalued · +40.5% margin of safety
Market outside MC distributionMarket $19.62 vs DCF $32.95 (post-governance, pre-gov $34.69). Even at the 5th-percentile Monte Carlo outcome ($27.10), intrinsic value exceeds today's price by 38%.
Sector Drugs (Pharmaceutical) — Generic + Branded MENACountry mix 🇺🇸 58% · 🇸🇦 10% · 🇩🇿 7%MC σ ±$2.88Governance 5% haircut
Intrinsic / share
$32.95
post 5% gov
Market / share
$19.62
last close
Margin of safety
+40.5%
vs intrinsic
Enterprise value
$9.01B
engine output
Cost of equity / debt
11.10 / 3.56%
β 1.17 · CRP 1.67%
Stable ROIC / g
14.0 / 4.2%
terminal state
What it sells, where it sells
Operating profile
InjectablesUS generic injectables · margin trough 35.3% → 31.0% → 27-28% guided 2026~50%
BrandedMENA brands · +10% rev 2025, margin 24.6% → 26.4%~32%
Hikma RxUS oral generics · margin 17.3% → ~20% guided 2026~18%
Country mix (revenue-weighted)
Quality profile & the two-sided argument
A five-axis read on the DCF's load-bearing assumptions, plus the bull-vs-bear case distilled into anchor bullets.
Quality snowflake (each axis 0–6)
Growth3/6$3.35B → $5.2B Y10 (~4.5% CAGR); mgmt $5B 2030 + 1y slip
Margin3/622% Y5+ — 750bp below pharma 29.5%, 300bp above generics 15-17%
Reinvest4/6S2C 1.4 (vs industry 1.11); MENA capacity pre-funded
Risk3/6WACC 9.06%; MENA CRP lifts vs UK pure; 5% gov haircut (light)
Terminal3/6ROC override 14% (vs engine-derived 24.1%); g at rf 4.2%
The two-sided case
Rewards / Bull anchors
- Cycle, not break — and the market is paying for break. $19.62 market vs $32.95 DCF is a 68% MoS; MC P(intrinsic
- Bedford OH 2028 underwrites the re-acceleration. 2026-27 trough years (~3% blended) flip to 2028-30 acceleration (~9% blended) as Bedford bag/liquid/lyo lines come online. Lands at $5.2B Y10 = mgmt's $5B 2030 target + 1y slippage (priced for the documented 500bp Injectables miss in 2025).
- Two-thirds of the business is already expanding margin. Branded core revenue +10% 2025 with margin 24.6 → 26.4%; Hikma Rx guided 17.3 → ~20% (+270bp on flat revenue). Injectables compression masks operating leverage already showing up in the other 50% of group profit.
- ROIC discipline + insider cash + active buyback. 5-yr avg ROIC 16.5%; Said Darwazah bought 530K shares @ 1,584p (£8.4M cash) Nov 2025; Mazen bought 200K @ 1,756p (£3.5M); $250M buyback ~25% executed in 8 weeks. Family is paying cash above current $19.62.
- Governance haircut is light (5%) on purpose. Darhold 27.04% is responsive not extractive — Chair/CEO separated 2018 AND 2026 in response to proxy pushback, 96% AGM support for Said, no minority-abuse history. Bear PT still ~$25 = +27%. You are paid to be wrong on the operational thesis.
Risks / Bear anchors
- Bedford OH regulatory/operational failure Single biggest dependency. FDA refusal to certify or 3y+ slip turns base into bear: $5B target slips to 2032, Y10 lands at $4.5B, equity collapses to $18-22 range.
- Injectables margin sticks at 2026 trough indefinitely Bear scenario: 27% Injectables forever + Branded slows to MENA-GDP. Consolidated 19% margin → equity ~$22. Management already withdrew the medium-term target — they see the risk too.
- Darhold concert party — Rule 9 dynamics 27.04% with annual waiver required; 43.4% of independent shareholders voted against in 2024. Take-private below DCF or related-party drift is the tail. 5% post-DCF haircut already priced.
- MENA geopolitical escalation Iran war shipping/insurance + Gulf governments mandating 6-month stockpiling. ~$100-200M working-capital strain; FX translation on 32.5% MENA revenue.
- US generic pricing reform (IRA expansion) IRA-style negotiation extending to generic injectables/orals lowers Rx margin floor 200bp. Current Rx guide 17.3 → 20% would compress back.
Thesis & open questions
Investment thesis
- Cycle, not break — and the market is paying for break. $19.62 market vs $32.95 DCF is a 68% MoS; MC P(intrinsic
- Bedford OH 2028 underwrites the re-acceleration. 2026-27 trough years (~3% blended) flip to 2028-30 acceleration (~9% blended) as Bedford bag/liquid/lyo lines come online. Lands at $5.2B Y10 = mgmt's $5B 2030 target + 1y slippage (priced for the documented 500bp Injectables miss in 2025).
- Two-thirds of the business is already expanding margin. Branded core revenue +10% 2025 with margin 24.6 → 26.4%; Hikma Rx guided 17.3 → ~20% (+270bp on flat revenue). Injectables compression masks operating leverage already showing up in the other 50% of group profit.
- ROIC discipline + insider cash + active buyback. 5-yr avg ROIC 16.5%; Said Darwazah bought 530K shares @ 1,584p (£8.4M cash) Nov 2025; Mazen bought 200K @ 1,756p (£3.5M); $250M buyback ~25% executed in 8 weeks. Family is paying cash above current $19.62.
- Governance haircut is light (5%) on purpose. Darhold 27.04% is responsive not extractive — Chair/CEO separated 2018 AND 2026 in response to proxy pushback, 96% AGM support for Said, no minority-abuse history. Bear PT still ~$25 = +27%. You are paid to be wrong on the operational thesis.
Key debates
Will Bedford OH come online productively in 2028?
Our view: Our view: yes — central year of the base case. A 1y slip → Y10 lands at $5B not $5.2B (base still works). A 3y slip → bear case becomes central. This is the single biggest dependency in the model.
Target op margin 22% — defensible vs both anchors?
Our view: Our view: yes, deliberately between them. 750bp below pharma median 29.5% (right haircut for 70%-generics book vs Pfizer/Lilly innovator anchor); 300bp above Teva/Viatris 15-17% (right premium for MENA-branded 26%+ specialty mix). ±1pp = ±10% equity. This is the single most-likely-wrong number.
Injectables margin floor — 27% or lower?
Our view: Our view: 27.5% trough 2026 → 30% by 2028 → hold. Management withdrew the medium-term Injectables target — cleanest signal that 30%+ is no longer underwritten. We do NOT model recovery to 36%.
Governance discount 5% vs 10-20%?
Our view: Our view: 5%. Insider buying in size at materially higher prices (1,584p / 1,756p vs $19.62 ≈ 1,460p) is monetary alignment, not verbal. Lagardère/Bolloré pattern is 15-20% with minority-abuse history; Hikma has none.
Terminal ROC 14% vs engine-derived 24.1%?
Our view: Our view: 14% is a deliberate downward haircut. Formula gives 0.22 × 1.4 × 0.77 = 24.1%, but corpus framing is explicit: 'Hikma has never demonstrated >18% sustained ROIC at scale.' 14% prices the 170bp/3y compression continuing for 5 more years before stabilising.
Risks to thesis
Bedford OH regulatory/operational failureHigh
Single biggest dependency. FDA refusal to certify or 3y+ slip turns base into bear: $5B target slips to 2032, Y10 lands at $4.5B, equity collapses to $18-22 range.
Injectables margin sticks at 2026 trough indefinitelyHigh
Bear scenario: 27% Injectables forever + Branded slows to MENA-GDP. Consolidated 19% margin → equity ~$22. Management already withdrew the medium-term target — they see the risk too.
Darhold concert party — Rule 9 dynamicsMed
27.04% with annual waiver required; 43.4% of independent shareholders voted against in 2024. Take-private below DCF or related-party drift is the tail. 5% post-DCF haircut already priced.
MENA geopolitical escalationMed
Iran war shipping/insurance + Gulf governments mandating 6-month stockpiling. ~$100-200M working-capital strain; FX translation on 32.5% MENA revenue.
US generic pricing reform (IRA expansion)Med
IRA-style negotiation extending to generic injectables/orals lowers Rx margin floor 200bp. Current Rx guide 17.3 → 20% would compress back.
Synthetic credit overstates ratingMed
Engine-derived WACC 9.06% via synthetic ratings approximates BBB; actual BBB from S&P+Fitch matches. If MENA CRP recalibration lifts WACC 30bp → equity −4-5%.
10-year forecast
Revenue + FCFF on the left axis; operating margin on the right axis.
Monte Carlo distribution
Mean $31.93 ± $2.88 · P(intrinsic < market) = 0.0% · 1000 iterations (0 failed).
⚠ Active diagnostic:
- terminal_growth (0.0420) >= risk_free_rate (0.0420); Damodaran's stable-growth ceiling is the risk-free rate
Cost of capital build
| Risk-free rate | 1.43% | implied from CE − β·(ERP+CRP) |
| Mature-market ERP (assumed) | ~6.60% | Damodaran 2026 global |
| Levered β | 1.1701 | |
| Weighted CRP | 1.67% | country mix × per-country |
| Cost of equity | 11.10% | |
| Pre-tax cost of debt | 3.56% | synth rating Aa2/AA |
| WACC | 9.06% | |
| Terminal growth | 4.20% | |
| Terminal ROIC | 14.00% |
Full year-by-year DCF
| Year | Revenue | Op mgn | EBIT | EBIT(1−t) | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | $3.50B | 20.6% | $722M | $566M | $108M | $459M | $421M |
| 2 | $3.66B | 21.0% | $767M | $602M | $112M | $489M | $411M |
| 3 | $3.82B | 21.3% | $815M | $639M | $118M | $521M | $402M |
| 4 | $3.99B | 21.7% | $865M | $678M | $123M | $555M | $393M |
| 5 | $4.17B | 22.0% | $918M | $720M | $128M | $591M | $383M |
| 6 | $4.36B | 22.0% | $959M | $746M | $134M | $612M | $363M |
| 7 | $4.56B | 22.0% | $1.00B | $772M | $140M | $632M | $345M |
| 8 | $4.76B | 22.0% | $1.05B | $800M | $146M | $654M | $326M |
| 9 | $4.98B | 22.0% | $1.09B | $829M | $153M | $676M | $309M |
| 10 | $5.20B | 22.0% | $1.14B | $858M | $160M | $698M | $293M |
Methodology & flags
Damodaran FCFF DCF, 10y explicit + perpetuity. R&D capitalisation: ON · Lease capitalisation: OFF · Failure-rate adjustment: OFF · ESO subtraction: OFF.